Publication: Proteomic-based stratification of intermediate-risk prostate cancer patients
Proteomic-based stratification of intermediate-risk prostate cancer patients
Date
Date
Date
Citations
Zhong, Q., Sun, R., Aref, A. T., Noor, Z., Anees, A., Zhu, Y., Lucas, N., Poulos, R. C., Lyu, M., Zhu, T., Chen, G.-B., Wang, Y., Ding, X., Rutishauser, D., Rupp, N. J., Rueschoff, J. H., Poyet, C., Hermanns, T., Fankhauser, C., … Wild, P. J. (2024). Proteomic-based stratification of intermediate-risk prostate cancer patients. Life Science Alliance, 7(2), e202302146. https://doi.org/10.26508/lsa.202302146
Abstract
Abstract
Abstract
Gleason grading is an important prognostic indicator for prostate adenocarcinoma and is crucial for patient treatment decisions. However, intermediate-risk patients diagnosed in the Gleason grade group (GG) 2 and GG3 can harbour either aggressive or non-aggressive disease, resulting in under- or overtreatment of a significant number of patients. Here, we performed proteomic, differential expression, machine learning, and survival analyses for 1,348 matched tumour and benign sample runs from 278 patients. Three proteins (F5, TMEM126B,
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Downloads
Views
Citations
Zhong, Q., Sun, R., Aref, A. T., Noor, Z., Anees, A., Zhu, Y., Lucas, N., Poulos, R. C., Lyu, M., Zhu, T., Chen, G.-B., Wang, Y., Ding, X., Rutishauser, D., Rupp, N. J., Rueschoff, J. H., Poyet, C., Hermanns, T., Fankhauser, C., … Wild, P. J. (2024). Proteomic-based stratification of intermediate-risk prostate cancer patients. Life Science Alliance, 7(2), e202302146. https://doi.org/10.26508/lsa.202302146